title: [The clinical effect of ATG and OKT3 on the treatment of refractory rejection after cadavaric kidney transplantation].
abstract: OBJECTIVE
  To observe the effect of ATG and OKT3 on the treatment of refractory rejection, including acute and chronic rejection after cadaveric kidney transplantation.
  
  
  METHODS
  87 patients with refractory rejection after cadaveric kidney transplantation were treated by using ATG (13 patients) and OKT3 (74). A total dose of 1 000 mg for ATG group or 45 mg for OKT3 group was administered for each patient.
  
  
  RESULTS
  Two accelerating rejection and acute rejection were reversed and 7 in the ATG group, 90.00% (27/30) and 90.47% (38/42) in the OKT3 group respectively. A significant difference of total reverse rates was seen between the ATG and OKT3 groups (69.23% verse 90.28%, P < 0.05). In retransplant patients, the reverse rate of acute rejection by OKT3 was 91.67% (11/12). But OKT3 did not show any effect in patients with chronic rejection.
  
  
  CONCLUSIONS
  OKT3 is better than ATG for reversing the refractory rejection, especially in retransplant patients, but it has no any effect on chronic rejection.
authors.affiliation: Department of Urology, General Hospital of People's Liberation Army, Beijing 100853.
authors.forename: J
authors.initials: J
authors.lastname: Ao
authors.forename: Y
authors.initials: Y
authors.lastname: Li
authors.forename: X
authors.initials: X
authors.lastname: Xiao
authors.forename: W
authors.initials: W
authors.lastname: Yang
mesh_terms: D000293:Adolescent; D000328:Adult; D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use*; D000961:Antilymphocyte Serum / Q000009:adverse effects / Q000627:therapeutic use*; D017252:CD3 Complex / Q000032:analysis / Q000276:immunology*; D015704:CD4 Antigens / Q000032:analysis; D016827:CD8 Antigens / Q000032:analysis; D002102:Cadaver; D002648:Child; D003967:Diarrhea / Q000139:chemically induced; D005260:Female; D005334:Fever / Q000139:chemically induced; D006084:Graft Rejection / Q000378:metabolism / Q000401:mortality / Q000517:prevention & control*; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D007376:Interleukin-2 / Q000378:metabolism; D015850:Interleukin-6 / Q000378:metabolism; D016030:Kidney Transplantation; D008297:Male; D008875:Middle Aged; D015996:Survival Rate; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000378:metabolism; D014554:Urination / Q000187:drug effects; D014839:Vomiting / Q000139:chemically induced
chemical_list: D000911:Antibodies, Monoclonal; D000961:Antilymphocyte Serum; D017252:CD3 Complex; D015704:CD4 Antigens; D016827:CD8 Antigens; D007166:Immunosuppressive Agents; D007376:Interleukin-2; D015850:Interleukin-6; D014409:Tumor Necrosis Factor-alpha